Company: PHR
Filing Date: 2025-09-05
Form Type: 10-Q
Source: 0001412408-25-000062
Chunk: 91

Company: Phreesia, Inc.
Filing Date: 2025-09-05
Form: 10-Q
Item: Part I, Item 1
Chunk 91
---
 2025, respectively. See Note 10 - Leases for additional information regarding finance leases.(c) Capitalized internal-use softwareFor the three months ended July 31, 2025 and 2024, capitalized costs related to the Company’s solutions was $3,609 and $4,030, respectively, of costs related to the Company’s solutions. For the six months ended July 31, 2025 and 2024, the Company capitalized $7,399 and $8,418, respectively, of costs related to the Company’s solutions.During the three months ended July 31, 2025 and 2024, amortization expense related to capitalized internal-use software was $3,259 and $2,511, respectively, and during the six months ended July 31, 2025 and 2024, was $6,281 and $4,790, respectively.(d) Intangible assets and goodwillThe following presents the details of intangible assets as of July 31, 2025 and January 31, 2025:Useful Life (years)July 31, 2025January 31, 2025Acquired technology5 to 7$9,310 $9,310 Customer relationship7 to 1517,940 17,940 License156,200 6,200 Trademarks153,100 3,100 Total intangible assets, gross carrying value$36,550 $36,550 Less: accumulated amortization(10,147)(8,407)Net carrying value$26,403 $28,143 The weighted average remaining useful life for acquired technology in years was 4.6 and 5.1 as of July 31, 2025 and January 31, 2025, respectively. The remaining useful life for customer relationships in years was 11.2 and 11.6 as of July 31, 2025 and January 31, 2025, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years was 11.4 and 11.8 as of July 31, 2025 and January 31, 2025, respectively. The remaining useful life for the trademarks in years was 13.0 and 13.5 as of July 31, 2025 and January 31, 2025, respectively.Amortization expense associated with intangible